Novo Nordisk and Anthropic announced a collaboration Wednesday aimed at accelerating the development of new medicines using the Claude AI model.

The companies said they will work together on drug discovery obstacles identified by Novo’s scientists and computational teams, building out purpose-built solutions for particular scientific workflows while also supporting biological reasoning. Novo will also use Anthropic’s models to strengthen AI-driven software development across the company.

“Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,” Novo Nordisk president and CEO Mike Doustdar said in a statement. “AI can help us increase productivity in R&D and compress the path from research to marketed product.”

As an initial step, Novo will test Claude Science for specific R&D workflows and focus on scientific problems where the combined capabilities of the two companies are expected to have the greatest impact, the company said. Novo said the arrangement incorporates data governance protocols and human oversight requirements so that AI use remains consistent with the company’s compliance standards.

Anthropic co-founder and CEO Dario Amodei framed the potential impact of the partnership in broad terms. “AI’s increasing capability brings with it the potential to compress a century’s worth of biological and medical breakthroughs into a decade,” he said in a statement.

The partnership adds to a string of AI collaborations Novo has pursued. According to The Wall Street Journal, the Danish drugmaker earlier this year struck a deal with OpenAI and also established an AI innovation hub with Amazon Web Services.

Anthropic launched Claude Science as a scientific research workbench that connects to more than 60 scientific databases and includes prebuilt toolkits for fields such as genomics, proteomics, structural biology, and cheminformatics. The workbench uses a primary agent that can spawn specialized sub-agents to divide workloads, with a dedicated reviewer agent that audits citations and calculations before any output reaches publication. Early users at institutions including the Allen Institute and the UCSF Brain Tumor Center reported significant reductions in research time for complex analytical tasks. Anthropic said Claude Science runs on existing Claude models, including Opus 4.8, and is not a new or specialized model.

The Anthropic-Novo partnership follows an earlier arrangement Anthropic reached with Bristol-Myers Squibb, which gave that drugmaker’s workforce access to Claude for research and drug development.